Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.
You may also be interested in...
FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful
FDA finds no faults with self-administration for the hereditary angioedema drug as it takes the new molecular entity to a June 23 advisory panel.
FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful
FDA finds no faults with self-administration for the hereditary angioedema drug as it takes the new molecular entity to a June 23 advisory panel.
M&A Fireworks: Shire Buys Jerini For €328 Million
Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”